We are a clinical stage oncology therapeutics company developing a paradigm shift in regards to the treatment of cancer
Lead Product Candidate – ATI01, is entering Phase II clinical development for NSCL cancer.
Ongoing Product Development – Pipeline of drug candidates targeting pancreatic, ovarian and colon.
Treatment Efficacy – Targeting metabolic dysfunction avoids the pitfalls of the broad toxicity of platinum-based therapies, enhances the cancer cells sensitivity to chemotherapy & immunotherapy and enhances p53 mediated cellular apoptosis in cancer cells.
Experienced Leadership – 100 years of combined pharma experience and 20 products commercialized including two of the best selling oncology drugs, Avastin and Tarceva.
Performance History – Over 1,200 patients safely and effectively treated in the U.S., Australia and South Africa.
The Problem – Targeting cancers with high mortality and limited treatment options
Meet Our Team
Meet Our Board of Directors
“We are constantly discovering and innovating to make a meaningful impact for the patients we serve. We are pushing the boundaries on what science and technology can do, making the impossible, possible.”
Lead product candidate for NSCL cancers
We targeting oncological metabolic dysfunction as a strategy for selective cellular apoptosis
Initially targeting four cancers that have poor outcomes and an unmet medical need
Experienced management team whom developed and launched multiple oncology therapies